

Influenza

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

Trial Status
Completed

Trial Runs In
15 Countries

Trial Identifier
NCT01715909 2012-002633-11
NV25719

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the pharmacokinetics and pharmacodynamics of oseltamivir (Tamiflu) in immunocompromised children, less than (<) 13 years of age, with confirmed influenza infection. Participants will be randomized to receive either the standard dose or triple dose of oseltamivir orally daily for a minimum of 5 days and up to 20 days. Infants <1 year of age will be randomized to the standard dose arm only.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT01715909 2012-002633-11 NV25719
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
<= 12 Years

Healthy Volunteers
No
